PriceTargets.com logo

MoonLake Immunotherapeutics - MLTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $79.00
  • Forecasted Upside: 49.82%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$52.73 As of 12/3/2024 01:09 PM ET
▼ -2.74 (-4.94%)

This chart shows the closing price for MLTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MoonLake Immunotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MLTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MLTX

Analyst Price Target is $79.00
▲ +49.82% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $79.00, with a high forecast of $104.00 and a low forecast of $62.00. The average price target represents a 49.82% upside from the last price of $52.73.

This chart shows the closing price for MLTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in MoonLake Immunotherapeutics. This rating has held steady since June 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
11/5/2024WedbushReiterated RatingOutperform ➝ Outperform$92.00 ➝ $73.00
11/4/2024WedbushUpgradeStrong-Buy
10/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
9/23/2024Cantor FitzgeraldReiterated RatingOverweight
9/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
9/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/26/2024Wolfe ResearchDowngradeOutperform ➝ Peer Perform
8/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$66.00 ➝ $62.00
7/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
6/25/2024OppenheimerInitiated CoverageOutperform$104.00
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
6/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
5/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00
4/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
4/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00
4/2/2024The Goldman Sachs GroupInitiated CoverageNeutral$62.00
3/13/2024WedbushReiterated RatingOutperform ➝ Outperform$92.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00
3/1/2024WedbushReiterated RatingOutperform ➝ Outperform$92.00
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$66.00
2/26/2024William BlairReiterated RatingOutperform$92.00
2/15/2024Wolfe ResearchInitiated CoverageOutperform$77.00
12/18/2023Stifel NicolausBoost TargetBuy ➝ Buy$66.00 ➝ $69.00
12/8/2023CitigroupInitiated CoverageBuy$72.00
12/1/2023WedbushReiterated RatingOutperform ➝ Outperform$92.00
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$75.00
11/16/2023WedbushBoost TargetOutperform ➝ Outperform$86.00 ➝ $92.00
11/15/2023GuggenheimBoost TargetBuy ➝ Buy$70.00 ➝ $77.00
11/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$78.00
11/6/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
11/2/2023Stifel NicolausInitiated CoverageBuy$74.00
10/16/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$76.00
10/13/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
10/2/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
9/14/2023Bryan, Garnier & CoDowngradeBuy ➝ Neutral
9/13/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$76.00
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$75.00
9/12/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
9/12/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$41.00 ➝ $59.00
8/31/2023Needham & Company LLCInitiated CoverageBuy$76.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$75.00
8/14/2023WedbushReiterated RatingOutperform ➝ Outperform$86.00
7/31/2023WedbushBoost TargetOutperform ➝ Outperform$61.00 ➝ $86.00
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$75.00
7/17/2023HC WainwrightBoost Target$37.00 ➝ $75.00
7/3/2023Cantor FitzgeraldBoost Target$29.00 ➝ $65.00
6/27/2023WedbushBoost Target$33.00 ➝ $61.00
6/27/2023BTIG ResearchBoost Target$36.00 ➝ $68.00
6/26/2023SVB SecuritiesBoost Target$28.00 ➝ $56.00
6/26/2023GuggenheimBoost Target$51.00 ➝ $65.00
6/15/2023BarclaysInitiated CoverageEqual Weight$28.00
5/4/202322nd Century GroupReiterated RatingReiterates
5/1/2023GuggenheimInitiated CoverageBuy
4/20/2023HC WainwrightBoost TargetBuy$28.00 ➝ $30.00
3/22/2023WedbushInitiated CoverageOutperform$33.00
3/21/2023HC WainwrightReiterated RatingBuy$28.00
3/9/2023BTIG ResearchInitiated CoverageBuy$36.00
3/6/2023Cantor FitzgeraldReiterated RatingOverweight$23.00
2/14/2023Cantor FitzgeraldInitiated CoverageOverweight$23.00
2/13/2023HC WainwrightReiterated RatingBuy$28.00
2/3/2023HC WainwrightReiterated RatingBuy$28.00
2/2/2023Bryan, Garnier & CoInitiated CoverageBuy$22.00
12/21/2022Lifesci CapitalReiterated RatingOutperform
11/11/2022Jefferies Financial GroupInitiated CoverageBuy$16.00
8/25/2022Leerink PartnersInitiated CoverageOutperform$17.00
7/21/2022HC WainwrightInitiated CoverageBuy$28.00
7/7/2022CowenInitiated CoverageOutperform
7/7/2022CowenInitiated CoverageOutperform
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 11 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 11 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

MoonLake Immunotherapeutics logo
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More

Today's Range

Now: $52.73
Low: $52.73
High: $56.00

50 Day Range

MA: $50.27
Low: $46.20
High: $55.47

52 Week Range

Now: $52.73
Low: $37.55
High: $64.98

Volume

76,002 shs

Average Volume

364,621 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of MoonLake Immunotherapeutics?

The following Wall Street sell-side analysts have issued reports on MoonLake Immunotherapeutics in the last twelve months: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Needham & Company LLC, Oppenheimer Holdings Inc., Stifel Nicolaus, The Goldman Sachs Group, Inc., Wedbush, William Blair, and Wolfe Research.
View the latest analyst ratings for MLTX.

What is the current price target for MoonLake Immunotherapeutics?

0 Wall Street analysts have set twelve-month price targets for MoonLake Immunotherapeutics in the last year. Their average twelve-month price target is $79.00, suggesting a possible upside of 49.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting MLTX will reach $104.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $62.00 for MoonLake Immunotherapeutics in the next year.
View the latest price targets for MLTX.

What is the current consensus analyst rating for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics currently has 2 hold ratings, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MLTX.

What other companies compete with MoonLake Immunotherapeutics?

Other companies that are similar to MoonLake Immunotherapeutics include Summit Therapeutics, Sarepta Therapeutics, Dr. Reddy's Laboratories, Vaxcyte and Catalent. Learn More about companies similar to MoonLake Immunotherapeutics.

How do I contact MoonLake Immunotherapeutics' investor relations team?

The company's listed phone number is 41-41-510-8022 and its investor relations email address is [email protected]. The official website for MoonLake Immunotherapeutics is www.moonlaketx.com. Learn More about contacing MoonLake Immunotherapeutics investor relations.